CHE
ChemedANYSE / Health Care Equipment & Services
Last Price
At close
2026-07-22
Current thesis
VITAS is reaccelerating, Medicare Cap pressure is easing, and capital return plus tuck-in acquisitions should support EPS growth faster than revenue growth.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-28 · AMC.
What can break
Roto-Rooter revenue and adjusted EBITDA declined in Q1, and elevated marketing expense could persist if lead mix keeps skewing toward paid internet channels.
Momentum
81
Value
60
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $443.00 · Bull $510.00 · Bear $360.00
Earnings
2026-07-28 · AMC
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $474.00
Why
Momentum81 · Δ7d +17.2
Value60 · Δ7d -0.4
Sentiment46 · Δ7d -2.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
81
26% active weight
Current posture
7d trendImproving
Δ7d
+17.2
Δ21d
+34.9
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.6
Sentiment
46
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
-8.9
Why this grade
Composite grade A. Momentum 81.4 / Value 59.9 / Sentiment 46.4
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$6.68B
Beta
0.44
Shares Out
13.27M
P/E (TTM)
23.2
P/S (TTM)
2.45
P/FCF (TTM)
18.81
Rev YoY
+1.6%
EPS YoY
-0.4%
Gross Margin
+29.7%
Op Margin
+13.9%
Net Debt
$80.24M
Current Ratio
0.85
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology